Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766924 | 0.95 | CYP4F2 (0.41) | CYP4F2CYP4A11TDP1SMN1; SMN2LMNA | |
| SCHEMBL23346295 | 0.89 | CYP4F2 (0.31) | CYP4F2CYP4A11TDP1 | |
| SCHEMBL6770429 | 0.84 | — | — | |
| SCHEMBL30823013 | 0.79 | LMNA (0.39) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| 1,4-Butanediol SCHEMBL575910 | 0.77 | ATR (0.39) | CYP4F2CYP4A11TDP1SMN1; SMN2LMNA | |
| 1,4-Butanediol SCHEMBL591024 | 0.77 | ATR (0.39) | CYP4F2CYP4A11TDP1SMN1; SMN2LMNA | |
| SCHEMBL14445011 | 0.76 | GGPS1 (0.43) | — | |
| SCHEMBL471927 | 0.76 | CYP4F2 (0.33) | CYP4F2CYP4A11TDP1SMN1; SMN2 | |
| SCHEMBL23475303 | 0.76 | GGPS1 (0.43) | — | |
| SCHEMBL6769713 | 0.76 | CYP4F2 (0.33) | CYP4F2CYP4A11TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040197293-A1 | Anionic polyurethanes with elastic property | L'OREAL S.A. (FR) | 2004-10-07 | — | — | US | claimed |
| US-20040197293-A1 | Anionic polyurethanes with elastic property | L'OREAL S.A. (FR) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197293-A1 | Anionic polyurethanes with elastic property | PUF60, PHOSPHO1, PLA2G2C | CYP4F2 4692/4885CYP4A11 4776/4885TDP1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.